原发性肝癌患者糖皮质激素和其受体检测及相关因素作用探讨
|
摘要
研究背景:肝细胞癌(Heptocellular carcinoma,HCC,简称肝癌)是我国常见的恶性肿瘤之一,严重威胁人们身体健康,但迄今为止除各种手术方法外,几乎没有有效的治疗药物。糖皮质激素(Glucocorticoid,GC)与肿瘤有着密切的关系,既往有研究报道糖皮质激素能够抑制肝癌细胞的增殖,诱导其凋亡,抑制人卵巢癌增殖并诱导其分化,可能参与抑制人乳腺癌细胞系细胞增殖的过程,抑制肿瘤细胞血管内皮生长因子。糖皮质激素受体(GR)在肿瘤细胞的信号传导、肿瘤相关基因表达和细胞凋亡等过程中发挥重要作用,故其与肿瘤的关系日益受到重视。Ho等观察到多数原发性肝癌的胞质中可发现GR,它是原发性肝癌切除术后的独立预后因素,GR阳性者较GR阴性者生存率低。糖皮质激素受体(GR)在肝肿瘤细胞中含量的研究结果不一,多数作者发现肝硬化病人GR含量下降,而肝细胞癌(hepaticcellular cancer,HCC)患者肝细胞的GR含量增加,糖皮质激素及其受体与肝癌治疗及预后之间的关系急需深入研究。
目的:研究原发性肝癌患者糖皮质激素和其糖皮质激素受体的变化及其受影响的机制。
方法:
1、原发性肝癌组79人和健康人组66人,清晨六点抽静脉血,分离血清,放射免疫法检测糖皮质激素水平。
2、分为原发性肝癌组和健康人组,每组各22人,清晨六点抽取静脉血,用流式细胞术检测血内糖皮质激素受体含量,并观察原发性肝癌患者13人在我科中药综合治疗后糖皮质激素受体含量的变化。
结果:
1、原发性肝癌患者糖皮质激素较健康人降低(P＜0.05),原发性肝癌患者糖皮质激素与其钾、乙型肝炎和肌酐相关,与乙型肝炎呈最大负相关,相关系数为—44.484。健康人糖皮质激素与其肌酐、性别、谷丙转氨酶相关,女性糖皮质激素要低于男性,相关系数为—62.747。原发性肝癌患者经中药治疗后糖皮质激素有所升高(P＜0.01)。
2、原发性肝癌患者糖皮质激素受体较健康人降低(P＜0.01),原发性肝癌患者糖皮质激素受体结合力较正常人升高(P＜0.01),原发性肝癌患者治疗后糖皮质激素受体升高(P＜0.01),原发性肝癌患者治疗前后糖皮质激素受体结合力差值无统计学意义(P＞0.5)。
结论:
1、原发性肝癌患者糖皮质激素水平降低,乙型肝炎可能是患者糖皮质激素降低的重要因素。
2、原发性肝癌患者糖皮质激素受体较健康人降低,分析原因可能与以下因素有关:①肝硬化,②肝癌本身导致肝功损害,③原发性肝癌患者GR结合力升高,可能为GR减少造成GR结合力反应性升高所致。
3、经过中医综合治疗后,原发性肝癌患者糖皮质激素水平及其受体有明显改变,并且与临床指标相关,提示对糖皮质激素及其受体影响有可能是中药疗效的一个重要作用靶点。但明确的治疗作用有待于后续对患者相关指标的追踪检测以及生存期及生活质量的随访来证实。
展望:
本研究初步检测了原发性肝癌患者糖皮质激素水平及其受体和受体结合力水平,并与相关病理因素进行了多元回归分析,为探索原发性肝癌患者GR降低与肝癌发病及治疗的关系提供了初步的实验依据。在后续工作中,我们将继续随访观察患者的生存期及生存质量等指标,对糖皮质激素及其受体水平高低与肝癌发展之间关系进行探讨,也将继续研究对原发性肝癌患者应用糖皮质激素的治疗作用及预防复发作用的意义。
Investigation background:Heptocellular carcinoma is one of common malignant tumors in our country, which seriously jeopardize people's health. So far, there has been almost no effectual therapeutic drug except to adopt various of operative measures yet. It has intimate relation between glucocorticoid and tumour, the previons research reports that glucocorticoid can inhibit proliferation and induce apoptosis of hepatoma carcinoma cell, inhibiting proliferation and inducing cell differentiation of human ovarian cancer. Besides, glucocorticoid may be involved in inhibiting proliferation on human breat cancer cell lines cell, and inhibit the growth of vascular endothelial factor of tumour cell. Glucocorticoid receptor is important to signal conduction of tumour cell and the related gene of tumour and apoptosis, so it has been paid great attention the relation between GR and tumour. Ho,et al. observed that GR is discovered in the cytoplasm of majority primary hepatic carcinoma patient, which is the independently prognosis factor after primary hepatic carcinoma carcinosectomy. the survival rate of GR masculine is lower than GR negative. It is found that the GR content in tumor of liver is different. Most writer find that the GR content is descend in patient of cirrhosis of liver, while the GR content is increased in the hepatic cellular cancer. We need make a deep study on the relationship between GC and its receptor and the treatment and prognosis in primary hepatic carcinoma.
Objective: To investigate the variation and mechanisms of effect on the glucocorticoid and it's glucocorticoid receptor (GR) of primary hepatic carcinoma patients.
Methods:
1. there are two group, one is consisted of 79 people who are primary hepatic carcinoma patients and the other group is consisted of 66 healthy people. We phlebotomize at six in the morning, then we separate blood serum and detect the glucocorticoid level by radioimmunity method.
2. They are devided into primary hepatic carcinoma patients group and healthy people group, each group contains 22 persons. We phlebotomize at six in the morning, and detect the GR content with flow cytometry and observe the change of the glucocorticoid receptor (GR) content in primary hepatic carcinoma patients with 13 people after traditional Chinese drug combined therapy in our department.
Results:
1 .The glucocorticoid in primary hepatic carcinoma patients is lower by(P<0.05) than in the healthy people, the glucocorticoid is related to potassium, serum hepatitis and creatinine,extremely largest inverse correlation with the serum hepatitis, the interrelated coefficient is—44.484. the glucocorticoid is related to creatinine, gender and ALT in healthy adult, the glucocorticoid is lower in the female people than in the male people, the interrelated coefficient is—62.747.the glucocorticoid is elevated after treatment of the traditional Chinese medicine in primary hepatic carcinoma patients (P<0.01).
2. The GR in primary hepatic carcinoma patients is lower by(P<0.01) than in healthy people. The GR combining power fluorescence in primary hepatic carcinoma patients is higher by(P<0.01) than in the health adult. The GR in primary hepatic carcinoma patients is elevated after treatment by(P<0.01).There is no discrepancy of GR combining power in primary hepatic carcinoma patients before and after treatment (P>0.5).
Conclusion:
1. The glucocorticoid in primary hepatic carcinoma patients is decreased and serum hepatitis is possiblly an important factor for glucocorticoid decreasing.
2. The GR of primary hepatic carcinoma patients is lower than that in the healthy people, and the possible reason maybe that (1) cirrhosis of liver, (2) hepatic carcinoma lead to the damage of liver function, (3) the GR combining power is elevated in primary hepatic carcinoma patients, and the reason maybe that the GR decreasing lead to the GR combining power heighting.
3. The GC and its receptor of primary hepatic carcinoma is changed obviously after combined therapy of traditional Chinese medicine. It reveals that influencing the GC and its receptor maybe an important effective target of curative effect of traditional Chinese medicine. But conclusive therapeutic action need be confirmed by detecting to correlated index of patient and following visiting duration and quality of life.
Prospect:
We initially detect the GC, its receptor primary hepatic carcinoma and GR combining power in this reseach and analysize the correlated patho-factors in multiple regression analysis, providing initially experimental data for exploring the relation between GR loss, invasion and therapy in primary hepatic carcinoma patients. In post-work, we will continue to flup and observe the duration and living quality et al indexs of the patient, approach the relationship between GC and its receptor level and development of hepatoma, and study the meaning of therapeutic action and prophylaxis relapse after applicating GC.
目的:研究原发性肝癌患者糖皮质激素和其糖皮质激素受体的变化及其受影响的机制。
方法:
1、原发性肝癌组79人和健康人组66人,清晨六点抽静脉血,分离血清,放射免疫法检测糖皮质激素水平。
2、分为原发性肝癌组和健康人组,每组各22人,清晨六点抽取静脉血,用流式细胞术检测血内糖皮质激素受体含量,并观察原发性肝癌患者13人在我科中药综合治疗后糖皮质激素受体含量的变化。
结果:
1、原发性肝癌患者糖皮质激素较健康人降低(P＜0.05),原发性肝癌患者糖皮质激素与其钾、乙型肝炎和肌酐相关,与乙型肝炎呈最大负相关,相关系数为—44.484。健康人糖皮质激素与其肌酐、性别、谷丙转氨酶相关,女性糖皮质激素要低于男性,相关系数为—62.747。原发性肝癌患者经中药治疗后糖皮质激素有所升高(P＜0.01)。
2、原发性肝癌患者糖皮质激素受体较健康人降低(P＜0.01),原发性肝癌患者糖皮质激素受体结合力较正常人升高(P＜0.01),原发性肝癌患者治疗后糖皮质激素受体升高(P＜0.01),原发性肝癌患者治疗前后糖皮质激素受体结合力差值无统计学意义(P＞0.5)。
结论:
1、原发性肝癌患者糖皮质激素水平降低,乙型肝炎可能是患者糖皮质激素降低的重要因素。
2、原发性肝癌患者糖皮质激素受体较健康人降低,分析原因可能与以下因素有关:①肝硬化,②肝癌本身导致肝功损害,③原发性肝癌患者GR结合力升高,可能为GR减少造成GR结合力反应性升高所致。
3、经过中医综合治疗后,原发性肝癌患者糖皮质激素水平及其受体有明显改变,并且与临床指标相关,提示对糖皮质激素及其受体影响有可能是中药疗效的一个重要作用靶点。但明确的治疗作用有待于后续对患者相关指标的追踪检测以及生存期及生活质量的随访来证实。
展望:
本研究初步检测了原发性肝癌患者糖皮质激素水平及其受体和受体结合力水平,并与相关病理因素进行了多元回归分析,为探索原发性肝癌患者GR降低与肝癌发病及治疗的关系提供了初步的实验依据。在后续工作中,我们将继续随访观察患者的生存期及生存质量等指标,对糖皮质激素及其受体水平高低与肝癌发展之间关系进行探讨,也将继续研究对原发性肝癌患者应用糖皮质激素的治疗作用及预防复发作用的意义。
Investigation background:Heptocellular carcinoma is one of common malignant tumors in our country, which seriously jeopardize people's health. So far, there has been almost no effectual therapeutic drug except to adopt various of operative measures yet. It has intimate relation between glucocorticoid and tumour, the previons research reports that glucocorticoid can inhibit proliferation and induce apoptosis of hepatoma carcinoma cell, inhibiting proliferation and inducing cell differentiation of human ovarian cancer. Besides, glucocorticoid may be involved in inhibiting proliferation on human breat cancer cell lines cell, and inhibit the growth of vascular endothelial factor of tumour cell. Glucocorticoid receptor is important to signal conduction of tumour cell and the related gene of tumour and apoptosis, so it has been paid great attention the relation between GR and tumour. Ho,et al. observed that GR is discovered in the cytoplasm of majority primary hepatic carcinoma patient, which is the independently prognosis factor after primary hepatic carcinoma carcinosectomy. the survival rate of GR masculine is lower than GR negative. It is found that the GR content in tumor of liver is different. Most writer find that the GR content is descend in patient of cirrhosis of liver, while the GR content is increased in the hepatic cellular cancer. We need make a deep study on the relationship between GC and its receptor and the treatment and prognosis in primary hepatic carcinoma.
Objective: To investigate the variation and mechanisms of effect on the glucocorticoid and it's glucocorticoid receptor (GR) of primary hepatic carcinoma patients.
Methods:
1. there are two group, one is consisted of 79 people who are primary hepatic carcinoma patients and the other group is consisted of 66 healthy people. We phlebotomize at six in the morning, then we separate blood serum and detect the glucocorticoid level by radioimmunity method.
2. They are devided into primary hepatic carcinoma patients group and healthy people group, each group contains 22 persons. We phlebotomize at six in the morning, and detect the GR content with flow cytometry and observe the change of the glucocorticoid receptor (GR) content in primary hepatic carcinoma patients with 13 people after traditional Chinese drug combined therapy in our department.
Results:
1 .The glucocorticoid in primary hepatic carcinoma patients is lower by(P<0.05) than in the healthy people, the glucocorticoid is related to potassium, serum hepatitis and creatinine,extremely largest inverse correlation with the serum hepatitis, the interrelated coefficient is—44.484. the glucocorticoid is related to creatinine, gender and ALT in healthy adult, the glucocorticoid is lower in the female people than in the male people, the interrelated coefficient is—62.747.the glucocorticoid is elevated after treatment of the traditional Chinese medicine in primary hepatic carcinoma patients (P<0.01).
2. The GR in primary hepatic carcinoma patients is lower by(P<0.01) than in healthy people. The GR combining power fluorescence in primary hepatic carcinoma patients is higher by(P<0.01) than in the health adult. The GR in primary hepatic carcinoma patients is elevated after treatment by(P<0.01).There is no discrepancy of GR combining power in primary hepatic carcinoma patients before and after treatment (P>0.5).
Conclusion:
1. The glucocorticoid in primary hepatic carcinoma patients is decreased and serum hepatitis is possiblly an important factor for glucocorticoid decreasing.
2. The GR of primary hepatic carcinoma patients is lower than that in the healthy people, and the possible reason maybe that (1) cirrhosis of liver, (2) hepatic carcinoma lead to the damage of liver function, (3) the GR combining power is elevated in primary hepatic carcinoma patients, and the reason maybe that the GR decreasing lead to the GR combining power heighting.
3. The GC and its receptor of primary hepatic carcinoma is changed obviously after combined therapy of traditional Chinese medicine. It reveals that influencing the GC and its receptor maybe an important effective target of curative effect of traditional Chinese medicine. But conclusive therapeutic action need be confirmed by detecting to correlated index of patient and following visiting duration and quality of life.
Prospect:
We initially detect the GC, its receptor primary hepatic carcinoma and GR combining power in this reseach and analysize the correlated patho-factors in multiple regression analysis, providing initially experimental data for exploring the relation between GR loss, invasion and therapy in primary hepatic carcinoma patients. In post-work, we will continue to flup and observe the duration and living quality et al indexs of the patient, approach the relationship between GC and its receptor level and development of hepatoma, and study the meaning of therapeutic action and prophylaxis relapse after applicating GC.
引文
[1]、吴孟超,吴东.原发性肝癌的外科治疗进展。临床外科杂志.2005;13(1):4-7.
[2]、封颖璐,凌昌全.国外医学肿瘤学分册.糖皮质激素受体与肿瘤.2004;31(4):267-269.
[3]、陈哨辉,曲志兵,陈宏志,等.肝细胞癌患者外周血性激素受体和糖皮质激素受体的含量.中国肿瘤生物治疗杂志.1997;4(1):68-70.
[4]、陈永兵,刘立新,严律南.逆转肝癌MDR的研究.中华肝胆外科杂志.2005;11(5):356-359.
[5]、滕红丽.原发性肝癌中医药临床研究进展.中国中医药信息杂志.2005;12(9):103-105.
[6]、姚泰.生理学.北京.人民卫生出版社.2005;591-596.
[7].Meier CA.Regulation of gene expression by nuclear hormone receptors[J].J Recept Sign Transd Res.1997;17(1-3):319-335.
[8].Stolte EH,Van Kemenade BM,Savelkoul HF,et al.Evolution of glucocorticoid receptors with different glucocortieoid sensitivity.J Endocrinol.2006;190(1):17-28.
[9]、徐仁宝.休克时糖皮质激素受体的变化及大剂量糖皮质激素抗休克治疗的受体机制.基础医学与临床.1998;18(1):5-10.
[10]、凌昌全,李敏,朱德增,等.阴阳虚证与糖皮质激素受体关系的临床与实验研究,浙江中西医结合杂志.2001;11(9):532.
[11]、凌昌全,李敏,谭金星,等.中药对糖皮质激素受体保护作用的实验研究,中国中西医结合杂志.1999;19(5):302.
[12]、张家庆,刘志民.阳虚患者单个核及多形核白细胞糖皮质激素受体改变.中西医结合杂志.1990;10(4):215.
[13]、凌昌全,陈哲,俞超芹,等.52例阴虚阳虚患者外周血混合白细胞糖皮质激素受体的实验观察.中医杂志.1998;39(10):619.
[14].Changquan Ling,Yong Li,Xiaoyan Zhu,et al.Ginsenosides may reverse the dexamethasone-induced down-regulation of glucocorticoid receptor.General and Comparative Endocrinology.2005;140:203-209.
[15]、李敏,凌昌全,黄雪强,等.人参茎叶皂甙苷对热损伤大鼠不同脏器糖皮质激素受体的影响.中西医结合学报.2006:4(2):156-159.
[16]、姚泰.生理学.北京.人民卫生出版社.2005:365.
[17]、郑冬,谭恩勋,张国材,等.糖皮质激素受体在淋巴瘤治疗中的意义.新医学.1998;29(2):49-50.
[18]、赵子彦,栾杨,路方红,等.老年人血清皮质醇水平与年龄、性别及疾病的相关性探讨.中国老年学杂志.2004;24(11):994-996.
[19]、蔡斌,陈佩杰.运动与糖皮质激素受体.中国临床康复.2002;6(15):2276-2277.
[20]、叶任高.内科学.北京.人民卫生出版社.2004;451。
[21]、朱梅,吴国,李莹.EH和CHD患者血浆糖皮质激素节律表达水平的临床分析.放射免疫学杂志.2007;20(3):209-210.
[22].De Kloet ER,Derijk R.Signaling pathways in brain involved in predisposition and pathogenesis of stressrelated disease:genetic and kineticfactors affecting the MR/GR balance.Ann N Y Acad Sci.2004;1032:14-34.
[23]、张绪清,王小红,李梦东,等.病毒性肝炎患者血清糖皮质激素检测的意义.中华肝病学会肝脏杂志.1995;3(2):113.
[24]、刘建军,王文新,吴静,等.肝炎肝硬化患者血浆糖皮质激素浓度变化与临床的关系.临床消化病杂志.1994;6(2):87-88.
[25].Forbes a,Wilkinson ML,Igbal MI,et al.Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone.Eur J Cancer ClinOncol.1987;23(11):1659-1664.
[26].Stricklan RW,Wahi LM,Finbloom DS.Corticosteroids enhance the bind of recombinant interferon-gama to cultured human monocytes.J Immuol.1986;137:1577-1580.
[27]、陈庆强,黄嘉瑜,陈力舟.地塞米松在晚期肝癌中的临床应用.中华现代中西医杂志.2004;2(3):265-266.
[28]、张俊峰,陈规划,陆敏强,等.甲基强的松龙对人肝癌HepG一2细胞增殖抑制机制的研究.中华实验外科杂志.2005;22(4):501.
[29]、于新娟,侯桂华.中药对糖皮质激素受体影响的研究进展.国外医学中医中药分册.2004;26(4):216-223.
[30]、朱世敏,唐志鹏.中医虚证、中药与糖皮质激素受体关系研究的初步进展.广东医学院学报.1997;15(3):223-225.
[31]、林世德,陈华嘉,李宁.流行性出血热患者白细胞糖皮质激素受体的观察.贵州医药.1997;21(5):268-270.
[32]、刘敏,丛志强,殷拥军,等.重症肌无力患者糖皮质激素受体含量与疗效的关系.中华神经科杂志.1999;32(2)96-98.
[33].Lui WY,Peng FK,Chang TJ,et al.Analysis of glucocorticoid receptors in human hepatocellular carcinoma and HepG2 cell.Hepatology.1993;18(5):1167-1174.
[34].Chi CW,Chang YF,Chao TW,et al.Folwcytometric and lysis of the effect of berberine on the expression of glucocorticoid receptors in hepatoma HepG2 cells.Life-Sci.1994;54:2099-107.
[35].Chou CK,Wang LH,Lin HM,et al.Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells.Hepatology.1992;16(1):13-18.
[36]、李久宏,李萍,李波,等.系统性红斑狼疮患者糖皮质激素受体与T淋巴细胞亚群的研究.中国麻风皮肤病杂志.2005;21(6):419-421.
[37]、王广欢,蒋学武,李建宏,等.血管瘤和血管畸形组织中糖皮质激素受体及其亚型的表达及意义.中华小儿外科杂志.2005:26(6):301-304.
[38]、黄士勤,张兴荣.外周血白细胞糖皮质激素受体与肝硬化关系的研究.镇江医学院学报.2000:10(3):425-426.
[1]cell ion channel and disease(3).modem clinical medical bioengineering magazine.2005;11(4):366-367.
细胞离子通道与疾病(3).现代临床医学生物工程学杂志.2005;11(4):366-367.
[2]Li JM,Liu CH,Shang ZL.the ion channel of cell membrane.hebei normal university journal(natural science edition).2005;29(5):520-522.
李俊敏,刘朝晖,尚忠林.细胞膜上的离子通道.河北师范大学学报(自然科学版).2005;29(5):520-522.
[3]滕红丽.原发性肝癌中医药临床研究进展.中国中医药信息杂志.2005,12(9):103-105.
[4]Xiao M,Zhang HY,Zhou NX.the progress of the ion channel disease.Journal of General Hospital of Air Force;Pla.2005;21(4):219-221.
肖梅,张洪义,周宁新.离子通道病的研究进展.空军总医院学报.2005;21(4):219-221.
[5]Roman RM,Smith RL,Feranchak AP,etal.C1C-2 chloride channels contribute to HTC cell volume homeostasis.Am J Physiol Gastrointest Liver Physiol.2001;280(3):G344-53.
[6]Tian J,Tao L,Cao YX,etal.the effect of the niflumic acid to the man cancer of the liver multiplication.Acta Physiologica Sinica.2003;55(2):160-164.
田晶,陶凌,曹云新,等.尼氟灭酸对肝癌细胞增殖的影响.生理学报.2003;55(2):160-164.
[7]Chen JL.calmodulin participate Reuber hepatoma carcinoma cell cistern maneuver calcium influx.Journal of Fujian Medical University.1999;33(3):233-237.
陈景龙.钙调蛋白参与Reuber肝癌细胞的池操纵钙内流.福建医科大学学报.1999;33(3):233-237.
[8]Zhang ZM,Qiu FZ.ion channel and disease.world chinese journal of digestology.2005;13(5):585-587.
张宗明,裘法祖.离子通道与疾病.世界华人消化杂志.2005;13(5):585-587.
[9]Wong ZP.Research Progress in potassium channels and tumor.Journal of International Pathology and Clinical Medicine.2005;25(6):488-491.
瓮占平.钾离子通道与肿瘤关系研究进展.国际病理科学与临床杂志.2005;25(6):488-491.
[10]Jia YS,Wei XL,Zhao J.Ion Channels and Tumor.Progress in Physiological Sciences.2007;8(3):229-234.
贾勇圣,魏晓莉,赵杰,等.离子通道与肿瘤.生理科学进展.2007;8(3):229-234.
[11]Lastraioli E,Guasti L,Crociani O,etal.Hergl gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells.Cancer Res.2004;64(2):606-11.
[12]Schwab A,Nechyporuk-Zloy V,Fabian A,etal.Cells move when ions and water flow.Pflugers Arch.2007;453(4):421-432.
[13]Masi A,Becchetti A,Restano-Cassulini R,etal.hERG1 channels are overexpressed in glioblastoma mulfiforme and modulate VEGF secretion in glioblastoma cell lines.Br J Cancer.2005;93(7):781-792.
[14]Fu W,Zhang ZM,Zhou PA,etal.the human being hepatoma carcinoma cell membrane ion channel characteristics of channel investigation.Beijing Medical University journal.1998;30(2):135-137.
傅卫,张宗明,周培爱,等.人肝癌细胞膜离子通道特性研究.北京医科大学学报.1998;30(2):135-137.
[15]Zhou Q,Kwan HY,Chan HC,etal.Blockage of voltage-gated K+ channels inhibits adhesion and proliferation of hepatocarcinoma cells.Int J Mol Med.2003;11(2):261-266.
[16]Ji TL,Xie MJ,Min J.reaseach about the man cancer of the liver HCC-9204 membrane kalium ion characteristics of channel.modem tumor medical science.2006;14(2):171-173.
姬统理,谢满江,闵婕,等.人肝癌HCC-9204细胞膜钾离子通道特性的研究.现代肿瘤医学.2006:14(2):171-173.
[17]Fu W,Zou XS,Zhang ZM,etal.the fuction of the delayed rectification kalium ion channel in the man cancer of the liver multiplication.Journal of Capital University of Medical Sciences.1999;31(4):315-317,334.
傅卫,周孝思,张宗明,等.延迟整流性K+通道在人肝癌细胞增殖中的作用.首都医科大学学报.1999;31(4):315-317,334.
[18]Rajasekaran SA,Palmer LG,Quan K,et al.Na,K-ATPase beta-subunit is required for epithelial polarization,suppression of invasion,and cell motility[J].Mol Biol Cell.2001;12(2):279-95.
[19]Yeh JY,Huang WJ,Kan SF,et al.Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells[J].Prostate 2003;1;54(2):112-124.
[20]Kawazoe N,Aiuchi T,Masuda Y,et al.Induction of apoptosis by bufalin in human tumor cells is associated with a change of intracellular concentration of Na+ ions[J].J Biochem(Tokyo).1999Aug;126(2):278-86.
[21]陈小义,徐瑞成,等.蟾蜍灵诱导人胃癌细胞凋亡的实验研究[J].基础医学与临床.2000; 20(5):50-53.
[22]Akiyama M,Ogura M,Iwai M,et al.Effect of bufalin on growth and differentiation of human skin carcinoma cells in vitro[J].Hum Cell.1999;12(4):205-209.
[23]Hashimoto S,Jing Y,Kawazoe N,et al.Bufalin reduces the level of topoisomerase Ⅱ in of human leukemia cells and affects the cytotoxicity of anticancer drugs.[J]Leuk Res.1997;21(9):875-883.
[24]Umazawa S,Inoue N,Nakura H,et al.A cardiotonic steroid bufalin-induced differentiation of THP-1 cells.Involvement of Na+,K(+)-ATPase inhibition in the early changes in proto-oncogene expression[J].Biochem Pharmacol.1996 Jul 26;52(2):321-329.
[25]Jing Y,Ohizumi H,Kawazoe N.Selective inhibitory effect of bufalin on growth of human tumor cells in vitro:association with the induction of apoptosis in leukemia HL-60 cells[J].Jpn J Cancer Res.1994;85(6):645-51.
[26]Zhang X,Huang Z,Li C.Antitumor activity of thevetoside in vitro[J].Chin Med J (Engl).1996;109(6):478-81.
[27]陈锐群,余竹元,张夏英,等.知母皂甙是Na-K-ATP酶的抑制剂[J].生物化学与生物物理学学报.1982;14:159-164.
[28]叶胜龙,汤钊猷.知母皂甙治疗人肝癌移植大鼠模型的观察[J].肿瘤.1988;8:259-260.
[29]吴孔明,张覃沐,王庆端,等.冬凌草甲素对肿瘤细胞钠泵活性的影响[J].肿瘤防治研究.1994.;21(4):208-209.
[30]Li N,Wu XF,Ma KJ,et al.The effect of Shensongyangxin capsule on potassium channel currents in isolated ventricular myocytes.Chinese Journal of Difficult and Complicated Cases.2007;6(3):133-137.
李宁,吴相锋,马克娟,等.参松养心胶囊对心室肌细胞钾通道的影响.疑难病杂志.2007;6(3):133-137.
[31]Zeng J,Huang XH,Lai H,etal.The empirical study progress of Sanqi Panax Notoginseng to ion channel and anti-arrhythmia effect.Journal of gannan medical college.2001;21(3):346-348.
曾靖,黄贤华,赖华,等.三七总皂甙对离子通道及抗心律失常作用的研究进展.赣南医学院学报.2001;21(3):346-348.
[32]Xu ZX.Research Renew of Chinese Herbs Acting on cadiocyte Calcium Channels.Chinese Journal of Traditional Medical Science and Technology.2003;10(6):388-389.
徐志鑫.心肌细胞钙通道中药研究现状.中国中医药科技.2003;10(6):388-389.
[33]Du ZM,Qiu XH,Li BX,etal.Protect effect of Guanxin capsule on myocardial ischemia in rats.Chinese Pharmaceutical Journal.2000;35(10):664.
杜智敏,邱晓红,李宝馨,等.冠心胶囊对大鼠心肌缺血的保护作用.中国药学杂志.2000;35(10): 664.
[34]Xu ZX,Luo RJ,Guan L.Research Renew of Chinese Herbs Acting on Calcium Channels.Chinese Journal of Basic Medicine in Traditional Chinese Medicine.2003;9(11):45-48.
徐志鑫,罗荣敬,关莉.作用于钙通道中药的研究现状.中国中医基础医学杂志.2003;9(11):45-48.
[35]Schonher R.Clinical relevance of ion channels for diagnosis and therapy of cancer.J Membr Biol.2005;205(3):175-84.
[36]Chen J.The empirical study progress of the traditional Chinese medicine inducing hepatoma carcinoma cell's apoptosis.Journal of Chinese Integrative Medicine.2004;2(4):301-303.
陈坚,中药诱导肝癌细胞凋亡的实验研究进展.中西医结合学报.2004:2(4):301-303.
[37]Wu MC.The problem ahout the chinese medicines,effect,position and existing in prevention and cure hepatoma.Journal of Chinese Integrative Medicine.2003;1(3):163-164.
吴孟超.中医药在肝癌防治中的作用、地位和存在的问题.中西医结合学报.2003:1(3):163-164.
[1]Yao T.physiology.Bei Jing.People's Medical Publishing House.2005;591-596.
姚泰.生理学.北京.人民卫生出版社.2005;591-596.
[2]Yao T.physiology.Bei Jing.People's Medical Publishing House.2005;365.
姚泰.生理学.北京.人民卫生出版社.2005:365.
[3]Wang JG,Yan TZ.Study on the relation of cortisol to hormone-refractory prostate cancer.Practical Journal of Medicine.2004;21(7):595-596.
王建功,闫天中.糖皮质激素与雄激素非依赖前列腺癌的关系.实用医药杂志.2004;21(7):595-596.
[4]Xue SQ,Yang CF,Zheng DX,et al.lung cancer and digestive canal cancer patient.Journal of Radioimmunology.1999;12(5):312-313.
薛昭卿,杨春富,郑东旭,等.肺癌及消化道癌肿患者手术前、后血清糖皮质激素检测及其意义.放射免疫学杂志.1999:12(5):312-313.
[5]Zhang WL,Wang YJ,Liu YJ.carcinoid of bellows induce hypercortisolism(multitude imageology examination method and diagnosis ).Heilongjiang Medical Journal.1999;12(186):9.
张文兰,王英杰,刘拥军.肺部类癌导致的糖皮质激素增多症(多种影像学检查方法和诊断).黑龙江医学.1999;12(186):9.
[6]Jin H,Gao LH,Meng QR.the correlation analysis of hepatoma patient plasma cortisol.testosterone content and T lymphocyte function.Chinese Journal of Hepatobiliary Surgery.2001;7(4):246-247.
金虎,高丽虹,孟庆润.肝癌病人血浆糖皮质激素、睾酮含量和T淋巴细胞功能的相关分析.中华肝胆外科杂志.2001;7(4):246-247.
[7]Chen QQ,Huang JY,Chen LZ.The clinical application of dexamethasone to the advanced stage cancer of the liver.Chinese Journal of Current Traditional and Western Medicine.2004;2(3):265-6.
陈庆强,黄嘉瑜,陈力舟.地塞米松在晚期肝癌中的临床应用.中华现代中西医杂志.2004:2(3):265-266.
[8]Zhang JF,Chen GH,Lu MQ,et al.Study of the Growth depression mechanism on Human Hepatocellular Carcinoma Cell Line HepG2 by Methylprednisolone.Chinese Journal of Experimental Surgery.2005;22(4):501.
张俊峰,陈规划,陆敏强,等.甲基强的松龙对人肝癌HepG-2细胞增殖抑制机制的研究.中华实验外科杂志.2005;22(4):501.
[9]Feng YL,Ling CQ,Li B,et al.Clinical Study on Integrative Medicine for Preventing and Treating Post--Transcatheter Arterial ChemoemBolizatio.Chinese Journal of Integrated Traditional and Western Medicine.2005;25(6):534-536.
封颖璐,凌昌全,李柏,等.中西医结合防治经动脉化疗栓塞术后综合征的研究.中国中西医结合杂志.2005;25(6):534-536.
[10]Gaunitz F,Heise K,Schumann R,et al.Glucocorticoid induced expression of glutamine synthetase in hepatoma cells.Biochem Biophys Res Commun.2002;296(4):1026-32.
[11]Rowling MJ,Schalinske KL.Retinoic acid and glucocorticoid treatment induce hepatic glycine N-methyltransferase and lower plasma homocysteine concentrations in rats and rat hepatoma cells.J Nutr.2003;133(11):3392-8.
[12]Xu MJ,Hui N,Liu YJ.corticoids on activation of extracellular signal--regulated kinase 1 / 2 and cell proliferation in a human breast cancer cell line:MCF--7.Journal of Chinese Modern Gynaecology and Obstetrics.2005;2(2):100-103.
徐明娟,惠宁,刘宇健.ERK通路的激活状态对糖皮质激素抑制人乳腺癌细胞系MCF-7细胞增殖状态的影响.中华现代妇产科学杂志.2005:2(2):100-103.
[13]Wang H,Wang Y,Raybum ER,Hill DL,et al.Dexamethasone as a chemosensitizer for breast cancer chemotherapy:potentiation of the antitumor activity of adriamycin.modulation of cytokine expression,and pharmacokinetics.Int J Oncol.2007;30(4):947-53.
[14]Unterholzner S,Willhauck MJ,Cengic N,et al.Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells.J Clin Endocrinol Metab.2006;91(1):69-78.
[15]Ouatas T,Halverson D,Steeg PS.Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells:new uses for old compounds.Clin Cancer Res.2003;9(10 Pt 1):3763-72.
[16]Xu MJ,Fang GN,Cui Y,etal,Regulation of glucocorticoid receptor expression by dexamethasone in a human ovarian carcinoma cell line,Shanghai Medical Journal,2003;26(1):53-55.
徐明娟,方国恩,崔英,等.地塞米松对人卵巢癌细胞糖皮质激素受体的调节.上海医学.2003:26(1):53-55.
[17]Xia B,Chen YX,Chen GC,etal.Effect of glucocorticoid on cell cycle of human ovarian cancer cell line HO-8910.Academic Journal of Second Military Medical University.2003;24(5):499-501.
夏冰,陈玉霞,陈光椿,等.糖皮质激素对人卵巢癌细胞系HO-8910细胞周期的影响.第二军医大学学报.2003;24(5):499-501.
[18]Li ZB,Xia B,Lu J.The action of transforming growth factor β1 signal path in the inhibitory effects of glucocorticoid on proliferation of human ovarian cancer cell line HO-8910.Chinese Journal of Pathophysiology.2003;19(11):1542-1543.
李宗斌,夏冰,卢建.转化生长因子β1信号通路在糖皮质激素抑制人卵巢癌细胞HO-8910增殖中的作用.中国病理生理杂志.2003;19(11):1542-1543.
[19]Xu MJ,Cui Y,Fang GE,et al.Efects ofglucecorticoid on differentiation of 3AO:a human ovarian carcinoma cell line.Shanghai Medical Journal.2003;26(4):265-267.
徐明娟,崔英,方国恩,等.糖皮质激素对人卵巢癌细胞系(3AO)的诱导分化作用.上海医学.2003;26(4):265-267.
[20]Xu MJ,Hui N,Liu A,et al.Effects of glucocorticoids on cell cycle and CDKI p21/WAF1 in a human ovarian cancer cell line:3AO.Shanghai Medical Journal.2006;29(7):483-485.
徐明娟,惠宁,刘安,等.糖皮质激素对人卵巢癌细胞系3AO细胞周期分布及细胞周期蛋白激酶抑制因子p21/WAF1表达的影响.上海医学.2006:29(7):483-485.
[21]Xia B,Lu J,Wang G.Glucocorticoid modulation of extracellular signal-regulated protein kinase 1/2 and p38 in human ovarian cancer HO-8910 cells.Chin Med J(Engl).2003;116(5):753-6.
[22]Saunders DE,Christensen C,Wappler NL,et al.Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3,retinoic acid and dexamethasone.Anticancer Drugs.1993;4(2):201-8.
[23]Chen YX,Li ZB,Diao F,et al.Mechanism of inhibiting proliferation of human ovarian cancer cells of the line HO-8910 by dexamethasone:the role of RhoB signaling pathway.Zhonghua Yi Xue Za Zhi.2006;86(20):1400-4.
[24]Skjoeth J,Bjerre PK.Effect of glucocotricoids on ICP in Patients with a cerebral tumor.Acta Neurol Scand.1997;96(3):167-170.
[25]Anderson c,Jensen FT.Differances in blood - tumor - bawier leage of human intra cranial tumors:quantative monitoring of vaso genic edema and itd response to glucocorticoed treatment.Acta Neurochirwien.1998;140(9):919-924.
[26]Ding XM,Zhao NH.the research progress of glucocorticoid on adjunctive therapy in Patients with a cerebral tumor.Foreign Medical Sciences Section on Neurology &Neurosurgery.2001;28(3):156 -159.
丁新民,赵宁辉.糖皮质激素在颅内肿瘤辅助治疗中的研究进展.国外医学神经病学神经外科学分册.2001;28(3):156-159.
[27]Li JW,Zao J.The clinical analysis of therapeutic alliance 62 cancer patient'sanorexy.The Medicine Magazine Of China.2006;4(10):610-611.
李君旺 赵剑.联合治疗62例癌症患者厌食的临床分析.中国医学杂志.2006;4(10):610-611.
[28]Bao J,Hao JQ,Peng WR,et al.Study on Safety of Glucocorticoids to Malignant Tumors Complicated with Diabetes Mellitus.Journal of Cancer Prevention and Treatment.2005;12(13):1003-1006.
鲍健,郝吉庆,彭万仁:,等.癌症合并糖尿病患者应用糖皮质激素安全性的前瞻性随机对照研究,肿瘤防治杂志.2005;12(13):1003-1006.
[29]Li JB,Wu JB,Feng SY,et al.Low dose of corticosteroid in combination with methotrexate for the treatment of tumor-stage MF.Journal of Clinical Dermatology.2006;35(5):329-330.
李晶冰,吴建斌,冯素英,等.小剂量糖皮质激素联合甲氨蝶呤治愈肿瘤期蕈样肉芽肿2例,临床皮肤科杂志.2006;35(5):329-330.
[30]Ran RQ,Wu YX,Fu H.the regulation of glucocorticoids to the receptor of TNF in gastric cancer cells.Chinese Journal of Immunology.1997;(13):81-83.
冉瑞琼,吴裕炘,付华.糖皮质激素对人胃癌细胞肿瘤坏死因子受体的调节.中国免疫学杂志.1997:(13):81-83.
[31]Li ZB,Wang SW,Lu J.Up--regulation of transforming growth factor--β_1type Ⅱ receptor by glucocorticoid and its biological significance in cancer cells.International Journal of Emergency and Critical Care Medicine.2006;(3):1264-1266.
[32]Wang Y,Chen YX,Diao F,et al.Inhibitory Effects of Dexamethasone on Growth of Human Prostate Cancer Cell Line PC-3:The Possible Mechanism.Academic Journal of Second Military Medical University.2006;27(8):885-887.
王燕,陈玉霞,刁飞,等.糖皮质激素抑制人前列腺癌PC-3细胞系增殖的可能机制.第二军医大学学报.2006;27(8):885-887.
[33]Lu YS,Lien HC,Yeh PY,et al.Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors.World J Gastroenterol.2005;11(40):6373-80.
[34]Davies S,Dai D,Pickett G,et al.Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells.Gynecol Oncol.2006;101(1):62-70.
[35]Zhang LY,Gao BL,Sun FQ,et al.the reseach of the prognosis of certain digestive canal cancer with hydrocortisone.immune function and social psychic factor.Sichuan Mental Health.1996;9(2):79-81.
张理义,高柏良,孙芳卿,等.某些消化道癌的预后与糖皮质激素、免疫功能及社会心理因素的研究.四川精神卫生.1996;9(2):79-81.
[36]Xu MJ,Hui N,Liu YJ,et al.Regulation of glucocorticoid receptor expression by dexamethasone in a human breast cancer cell line MCF-7.Shanghai Medical Journal.2006;29(3):173-175.
徐明娟,惠宁,刘宇健,等.人乳腺癌细胞系MCF-7细胞中糖皮质激素受体的表达及其调节.上海医学.2006;29(3):173-175.
[37]Luo YL,Cao LS,Xue XY,et al.adrenal cortical tumor hypercortisolism(Report of 28 Cases).Journal of Fujian Medical College.1995;29(2):170-171.
罗义麟,曹林升,薛学义,等.肾上腺皮质肿瘤糖皮质激素症28例报告.福建医学院学报.1995:29(2):170-171.
[38]Jang XY,He HM,Xu FY,et al.the serum cortisol RIA of esophageal carcinoma perioperatively.Journal of Radioimmunology.1994;7(2):126-127.
姜秀云,何浩明,徐风英,等.食管癌手术前后血清糖皮质激素RIA.放射免疫学杂志.1994;7(2):126-127.
[39]Zhang C,Kolb A,Mattem J,et al.Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy.Cancer Lett.2006;242(1):104-11.
[40]Lui WY,Chi CW,Chang YF,et al.In vivo and in vitro growth stimulation of murine hepatoma cells by glucocorticoid.Anticancer Res.2002;22(3):1413-22.
[41]Iida N,Sugiyama A,Myoubudani H,et al.Suppression of arachidonic acid cascade-mediated apoptosis in aflatoxin B1-induced rat hepatoma cells by glucocorticoids.Carcinogenesis.1998;19(7):1191-202.
[42]Ioannesyants IA,Polevaya EB.Sensitivity of peripheral blood lymphocytes from breast cancer patients to glucocorticoids.Bull Exp Biol Med.2006;141(1):73-6.
[43]Pang D,Kocherginsky M,Krausz T,et al.Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis.Cancer Biol Ther.2006;5(8):933-40.
[44]Rodriguez F,Redondo M,Ruiz-Cabello F.Dexamethasone induces altered binding of regulatory factors to HLA class I enhancer sequence in MCF-7 breast tumour cell line.Cancer Immunol Immunother.1998;46(4):194-200.
[45]Sui M,Chen F,Chen Z,et al.Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.Int J Cancer.2006;119(3):712-7.
[46]Zhang C,Marme A,Wenger T,et al.Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas.Int J Oncol.2006;28(2):551-8.
[47]Runnebaum IB,Bruning A.Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.Clin Cancer Res.2005;11(17):6325-32.
[48]Millard RJ,McCredie S.Bladder cancer in patients on low-dose methotrexate and cortico- steroids.Lancet.1994;343(8907):1222-1223.
[49]Nesher,M;Shpolansky,U;Rosen,H,et al.The digitalis-like steroid hormones:New mechanisms of action and biological significance.Life Sciences.2007;80(23):2093-107.
[50]Gu w,Han KQ,Su YH,etal.Inhibition Action of Bufalin on Human Transplanted Hepatocellular Tumor and Its Effects on Expressions of Bcl-2 and Bax Proteins in Nude Mice.Journal of Chinese Integrative Medicine.2007;5(2):155-159.
顾伟,韩克起,苏永华,等.蟾毒灵对裸鼠人肝癌移植瘤的抑制作用及对Bc-122利Bax蛋白表达的影响.中西医结合学报.2007;5(2):155-159.
[51].Weidemann H,Salomon N,Avnit-Sagi T,etc.Diverse effects of stress and additional adrenocorticotropic hormone on digitalis-like compounds in normal and nude mice[J].J Neuroendocrinol.2004;16(5):458-63.
[52].Weidemann H.Na/K-ATPase,endogenous digitalis like compounds and cancer development -- a hypothesis[J].Front Biosci.2005;10:2165-76.
[53]Wu MC.The problem ahout the chinese medicines,effect,position and existing in prevention and cure hepatoma.Journal of Chinese Integrative Medicine.2003;1(3):163-164.
吴孟超.中医药在肝癌防治中的作用、地位和存在的问题.中西医结合学报.2003;1(3):163-164.
[2]、封颖璐,凌昌全.国外医学肿瘤学分册.糖皮质激素受体与肿瘤.2004;31(4):267-269.
[3]、陈哨辉,曲志兵,陈宏志,等.肝细胞癌患者外周血性激素受体和糖皮质激素受体的含量.中国肿瘤生物治疗杂志.1997;4(1):68-70.
[4]、陈永兵,刘立新,严律南.逆转肝癌MDR的研究.中华肝胆外科杂志.2005;11(5):356-359.
[5]、滕红丽.原发性肝癌中医药临床研究进展.中国中医药信息杂志.2005;12(9):103-105.
[6]、姚泰.生理学.北京.人民卫生出版社.2005;591-596.
[7].Meier CA.Regulation of gene expression by nuclear hormone receptors[J].J Recept Sign Transd Res.1997;17(1-3):319-335.
[8].Stolte EH,Van Kemenade BM,Savelkoul HF,et al.Evolution of glucocorticoid receptors with different glucocortieoid sensitivity.J Endocrinol.2006;190(1):17-28.
[9]、徐仁宝.休克时糖皮质激素受体的变化及大剂量糖皮质激素抗休克治疗的受体机制.基础医学与临床.1998;18(1):5-10.
[10]、凌昌全,李敏,朱德增,等.阴阳虚证与糖皮质激素受体关系的临床与实验研究,浙江中西医结合杂志.2001;11(9):532.
[11]、凌昌全,李敏,谭金星,等.中药对糖皮质激素受体保护作用的实验研究,中国中西医结合杂志.1999;19(5):302.
[12]、张家庆,刘志民.阳虚患者单个核及多形核白细胞糖皮质激素受体改变.中西医结合杂志.1990;10(4):215.
[13]、凌昌全,陈哲,俞超芹,等.52例阴虚阳虚患者外周血混合白细胞糖皮质激素受体的实验观察.中医杂志.1998;39(10):619.
[14].Changquan Ling,Yong Li,Xiaoyan Zhu,et al.Ginsenosides may reverse the dexamethasone-induced down-regulation of glucocorticoid receptor.General and Comparative Endocrinology.2005;140:203-209.
[15]、李敏,凌昌全,黄雪强,等.人参茎叶皂甙苷对热损伤大鼠不同脏器糖皮质激素受体的影响.中西医结合学报.2006:4(2):156-159.
[16]、姚泰.生理学.北京.人民卫生出版社.2005:365.
[17]、郑冬,谭恩勋,张国材,等.糖皮质激素受体在淋巴瘤治疗中的意义.新医学.1998;29(2):49-50.
[18]、赵子彦,栾杨,路方红,等.老年人血清皮质醇水平与年龄、性别及疾病的相关性探讨.中国老年学杂志.2004;24(11):994-996.
[19]、蔡斌,陈佩杰.运动与糖皮质激素受体.中国临床康复.2002;6(15):2276-2277.
[20]、叶任高.内科学.北京.人民卫生出版社.2004;451。
[21]、朱梅,吴国,李莹.EH和CHD患者血浆糖皮质激素节律表达水平的临床分析.放射免疫学杂志.2007;20(3):209-210.
[22].De Kloet ER,Derijk R.Signaling pathways in brain involved in predisposition and pathogenesis of stressrelated disease:genetic and kineticfactors affecting the MR/GR balance.Ann N Y Acad Sci.2004;1032:14-34.
[23]、张绪清,王小红,李梦东,等.病毒性肝炎患者血清糖皮质激素检测的意义.中华肝病学会肝脏杂志.1995;3(2):113.
[24]、刘建军,王文新,吴静,等.肝炎肝硬化患者血浆糖皮质激素浓度变化与临床的关系.临床消化病杂志.1994;6(2):87-88.
[25].Forbes a,Wilkinson ML,Igbal MI,et al.Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5 alpha-dihydrotestosterone.Eur J Cancer ClinOncol.1987;23(11):1659-1664.
[26].Stricklan RW,Wahi LM,Finbloom DS.Corticosteroids enhance the bind of recombinant interferon-gama to cultured human monocytes.J Immuol.1986;137:1577-1580.
[27]、陈庆强,黄嘉瑜,陈力舟.地塞米松在晚期肝癌中的临床应用.中华现代中西医杂志.2004;2(3):265-266.
[28]、张俊峰,陈规划,陆敏强,等.甲基强的松龙对人肝癌HepG一2细胞增殖抑制机制的研究.中华实验外科杂志.2005;22(4):501.
[29]、于新娟,侯桂华.中药对糖皮质激素受体影响的研究进展.国外医学中医中药分册.2004;26(4):216-223.
[30]、朱世敏,唐志鹏.中医虚证、中药与糖皮质激素受体关系研究的初步进展.广东医学院学报.1997;15(3):223-225.
[31]、林世德,陈华嘉,李宁.流行性出血热患者白细胞糖皮质激素受体的观察.贵州医药.1997;21(5):268-270.
[32]、刘敏,丛志强,殷拥军,等.重症肌无力患者糖皮质激素受体含量与疗效的关系.中华神经科杂志.1999;32(2)96-98.
[33].Lui WY,Peng FK,Chang TJ,et al.Analysis of glucocorticoid receptors in human hepatocellular carcinoma and HepG2 cell.Hepatology.1993;18(5):1167-1174.
[34].Chi CW,Chang YF,Chao TW,et al.Folwcytometric and lysis of the effect of berberine on the expression of glucocorticoid receptors in hepatoma HepG2 cells.Life-Sci.1994;54:2099-107.
[35].Chou CK,Wang LH,Lin HM,et al.Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells.Hepatology.1992;16(1):13-18.
[36]、李久宏,李萍,李波,等.系统性红斑狼疮患者糖皮质激素受体与T淋巴细胞亚群的研究.中国麻风皮肤病杂志.2005;21(6):419-421.
[37]、王广欢,蒋学武,李建宏,等.血管瘤和血管畸形组织中糖皮质激素受体及其亚型的表达及意义.中华小儿外科杂志.2005:26(6):301-304.
[38]、黄士勤,张兴荣.外周血白细胞糖皮质激素受体与肝硬化关系的研究.镇江医学院学报.2000:10(3):425-426.
[1]cell ion channel and disease(3).modem clinical medical bioengineering magazine.2005;11(4):366-367.
细胞离子通道与疾病(3).现代临床医学生物工程学杂志.2005;11(4):366-367.
[2]Li JM,Liu CH,Shang ZL.the ion channel of cell membrane.hebei normal university journal(natural science edition).2005;29(5):520-522.
李俊敏,刘朝晖,尚忠林.细胞膜上的离子通道.河北师范大学学报(自然科学版).2005;29(5):520-522.
[3]滕红丽.原发性肝癌中医药临床研究进展.中国中医药信息杂志.2005,12(9):103-105.
[4]Xiao M,Zhang HY,Zhou NX.the progress of the ion channel disease.Journal of General Hospital of Air Force;Pla.2005;21(4):219-221.
肖梅,张洪义,周宁新.离子通道病的研究进展.空军总医院学报.2005;21(4):219-221.
[5]Roman RM,Smith RL,Feranchak AP,etal.C1C-2 chloride channels contribute to HTC cell volume homeostasis.Am J Physiol Gastrointest Liver Physiol.2001;280(3):G344-53.
[6]Tian J,Tao L,Cao YX,etal.the effect of the niflumic acid to the man cancer of the liver multiplication.Acta Physiologica Sinica.2003;55(2):160-164.
田晶,陶凌,曹云新,等.尼氟灭酸对肝癌细胞增殖的影响.生理学报.2003;55(2):160-164.
[7]Chen JL.calmodulin participate Reuber hepatoma carcinoma cell cistern maneuver calcium influx.Journal of Fujian Medical University.1999;33(3):233-237.
陈景龙.钙调蛋白参与Reuber肝癌细胞的池操纵钙内流.福建医科大学学报.1999;33(3):233-237.
[8]Zhang ZM,Qiu FZ.ion channel and disease.world chinese journal of digestology.2005;13(5):585-587.
张宗明,裘法祖.离子通道与疾病.世界华人消化杂志.2005;13(5):585-587.
[9]Wong ZP.Research Progress in potassium channels and tumor.Journal of International Pathology and Clinical Medicine.2005;25(6):488-491.
瓮占平.钾离子通道与肿瘤关系研究进展.国际病理科学与临床杂志.2005;25(6):488-491.
[10]Jia YS,Wei XL,Zhao J.Ion Channels and Tumor.Progress in Physiological Sciences.2007;8(3):229-234.
贾勇圣,魏晓莉,赵杰,等.离子通道与肿瘤.生理科学进展.2007;8(3):229-234.
[11]Lastraioli E,Guasti L,Crociani O,etal.Hergl gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells.Cancer Res.2004;64(2):606-11.
[12]Schwab A,Nechyporuk-Zloy V,Fabian A,etal.Cells move when ions and water flow.Pflugers Arch.2007;453(4):421-432.
[13]Masi A,Becchetti A,Restano-Cassulini R,etal.hERG1 channels are overexpressed in glioblastoma mulfiforme and modulate VEGF secretion in glioblastoma cell lines.Br J Cancer.2005;93(7):781-792.
[14]Fu W,Zhang ZM,Zhou PA,etal.the human being hepatoma carcinoma cell membrane ion channel characteristics of channel investigation.Beijing Medical University journal.1998;30(2):135-137.
傅卫,张宗明,周培爱,等.人肝癌细胞膜离子通道特性研究.北京医科大学学报.1998;30(2):135-137.
[15]Zhou Q,Kwan HY,Chan HC,etal.Blockage of voltage-gated K+ channels inhibits adhesion and proliferation of hepatocarcinoma cells.Int J Mol Med.2003;11(2):261-266.
[16]Ji TL,Xie MJ,Min J.reaseach about the man cancer of the liver HCC-9204 membrane kalium ion characteristics of channel.modem tumor medical science.2006;14(2):171-173.
姬统理,谢满江,闵婕,等.人肝癌HCC-9204细胞膜钾离子通道特性的研究.现代肿瘤医学.2006:14(2):171-173.
[17]Fu W,Zou XS,Zhang ZM,etal.the fuction of the delayed rectification kalium ion channel in the man cancer of the liver multiplication.Journal of Capital University of Medical Sciences.1999;31(4):315-317,334.
傅卫,周孝思,张宗明,等.延迟整流性K+通道在人肝癌细胞增殖中的作用.首都医科大学学报.1999;31(4):315-317,334.
[18]Rajasekaran SA,Palmer LG,Quan K,et al.Na,K-ATPase beta-subunit is required for epithelial polarization,suppression of invasion,and cell motility[J].Mol Biol Cell.2001;12(2):279-95.
[19]Yeh JY,Huang WJ,Kan SF,et al.Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells[J].Prostate 2003;1;54(2):112-124.
[20]Kawazoe N,Aiuchi T,Masuda Y,et al.Induction of apoptosis by bufalin in human tumor cells is associated with a change of intracellular concentration of Na+ ions[J].J Biochem(Tokyo).1999Aug;126(2):278-86.
[21]陈小义,徐瑞成,等.蟾蜍灵诱导人胃癌细胞凋亡的实验研究[J].基础医学与临床.2000; 20(5):50-53.
[22]Akiyama M,Ogura M,Iwai M,et al.Effect of bufalin on growth and differentiation of human skin carcinoma cells in vitro[J].Hum Cell.1999;12(4):205-209.
[23]Hashimoto S,Jing Y,Kawazoe N,et al.Bufalin reduces the level of topoisomerase Ⅱ in of human leukemia cells and affects the cytotoxicity of anticancer drugs.[J]Leuk Res.1997;21(9):875-883.
[24]Umazawa S,Inoue N,Nakura H,et al.A cardiotonic steroid bufalin-induced differentiation of THP-1 cells.Involvement of Na+,K(+)-ATPase inhibition in the early changes in proto-oncogene expression[J].Biochem Pharmacol.1996 Jul 26;52(2):321-329.
[25]Jing Y,Ohizumi H,Kawazoe N.Selective inhibitory effect of bufalin on growth of human tumor cells in vitro:association with the induction of apoptosis in leukemia HL-60 cells[J].Jpn J Cancer Res.1994;85(6):645-51.
[26]Zhang X,Huang Z,Li C.Antitumor activity of thevetoside in vitro[J].Chin Med J (Engl).1996;109(6):478-81.
[27]陈锐群,余竹元,张夏英,等.知母皂甙是Na-K-ATP酶的抑制剂[J].生物化学与生物物理学学报.1982;14:159-164.
[28]叶胜龙,汤钊猷.知母皂甙治疗人肝癌移植大鼠模型的观察[J].肿瘤.1988;8:259-260.
[29]吴孔明,张覃沐,王庆端,等.冬凌草甲素对肿瘤细胞钠泵活性的影响[J].肿瘤防治研究.1994.;21(4):208-209.
[30]Li N,Wu XF,Ma KJ,et al.The effect of Shensongyangxin capsule on potassium channel currents in isolated ventricular myocytes.Chinese Journal of Difficult and Complicated Cases.2007;6(3):133-137.
李宁,吴相锋,马克娟,等.参松养心胶囊对心室肌细胞钾通道的影响.疑难病杂志.2007;6(3):133-137.
[31]Zeng J,Huang XH,Lai H,etal.The empirical study progress of Sanqi Panax Notoginseng to ion channel and anti-arrhythmia effect.Journal of gannan medical college.2001;21(3):346-348.
曾靖,黄贤华,赖华,等.三七总皂甙对离子通道及抗心律失常作用的研究进展.赣南医学院学报.2001;21(3):346-348.
[32]Xu ZX.Research Renew of Chinese Herbs Acting on cadiocyte Calcium Channels.Chinese Journal of Traditional Medical Science and Technology.2003;10(6):388-389.
徐志鑫.心肌细胞钙通道中药研究现状.中国中医药科技.2003;10(6):388-389.
[33]Du ZM,Qiu XH,Li BX,etal.Protect effect of Guanxin capsule on myocardial ischemia in rats.Chinese Pharmaceutical Journal.2000;35(10):664.
杜智敏,邱晓红,李宝馨,等.冠心胶囊对大鼠心肌缺血的保护作用.中国药学杂志.2000;35(10): 664.
[34]Xu ZX,Luo RJ,Guan L.Research Renew of Chinese Herbs Acting on Calcium Channels.Chinese Journal of Basic Medicine in Traditional Chinese Medicine.2003;9(11):45-48.
徐志鑫,罗荣敬,关莉.作用于钙通道中药的研究现状.中国中医基础医学杂志.2003;9(11):45-48.
[35]Schonher R.Clinical relevance of ion channels for diagnosis and therapy of cancer.J Membr Biol.2005;205(3):175-84.
[36]Chen J.The empirical study progress of the traditional Chinese medicine inducing hepatoma carcinoma cell's apoptosis.Journal of Chinese Integrative Medicine.2004;2(4):301-303.
陈坚,中药诱导肝癌细胞凋亡的实验研究进展.中西医结合学报.2004:2(4):301-303.
[37]Wu MC.The problem ahout the chinese medicines,effect,position and existing in prevention and cure hepatoma.Journal of Chinese Integrative Medicine.2003;1(3):163-164.
吴孟超.中医药在肝癌防治中的作用、地位和存在的问题.中西医结合学报.2003:1(3):163-164.
[1]Yao T.physiology.Bei Jing.People's Medical Publishing House.2005;591-596.
姚泰.生理学.北京.人民卫生出版社.2005;591-596.
[2]Yao T.physiology.Bei Jing.People's Medical Publishing House.2005;365.
姚泰.生理学.北京.人民卫生出版社.2005:365.
[3]Wang JG,Yan TZ.Study on the relation of cortisol to hormone-refractory prostate cancer.Practical Journal of Medicine.2004;21(7):595-596.
王建功,闫天中.糖皮质激素与雄激素非依赖前列腺癌的关系.实用医药杂志.2004;21(7):595-596.
[4]Xue SQ,Yang CF,Zheng DX,et al.lung cancer and digestive canal cancer patient.Journal of Radioimmunology.1999;12(5):312-313.
薛昭卿,杨春富,郑东旭,等.肺癌及消化道癌肿患者手术前、后血清糖皮质激素检测及其意义.放射免疫学杂志.1999:12(5):312-313.
[5]Zhang WL,Wang YJ,Liu YJ.carcinoid of bellows induce hypercortisolism(multitude imageology examination method and diagnosis ).Heilongjiang Medical Journal.1999;12(186):9.
张文兰,王英杰,刘拥军.肺部类癌导致的糖皮质激素增多症(多种影像学检查方法和诊断).黑龙江医学.1999;12(186):9.
[6]Jin H,Gao LH,Meng QR.the correlation analysis of hepatoma patient plasma cortisol.testosterone content and T lymphocyte function.Chinese Journal of Hepatobiliary Surgery.2001;7(4):246-247.
金虎,高丽虹,孟庆润.肝癌病人血浆糖皮质激素、睾酮含量和T淋巴细胞功能的相关分析.中华肝胆外科杂志.2001;7(4):246-247.
[7]Chen QQ,Huang JY,Chen LZ.The clinical application of dexamethasone to the advanced stage cancer of the liver.Chinese Journal of Current Traditional and Western Medicine.2004;2(3):265-6.
陈庆强,黄嘉瑜,陈力舟.地塞米松在晚期肝癌中的临床应用.中华现代中西医杂志.2004:2(3):265-266.
[8]Zhang JF,Chen GH,Lu MQ,et al.Study of the Growth depression mechanism on Human Hepatocellular Carcinoma Cell Line HepG2 by Methylprednisolone.Chinese Journal of Experimental Surgery.2005;22(4):501.
张俊峰,陈规划,陆敏强,等.甲基强的松龙对人肝癌HepG-2细胞增殖抑制机制的研究.中华实验外科杂志.2005;22(4):501.
[9]Feng YL,Ling CQ,Li B,et al.Clinical Study on Integrative Medicine for Preventing and Treating Post--Transcatheter Arterial ChemoemBolizatio.Chinese Journal of Integrated Traditional and Western Medicine.2005;25(6):534-536.
封颖璐,凌昌全,李柏,等.中西医结合防治经动脉化疗栓塞术后综合征的研究.中国中西医结合杂志.2005;25(6):534-536.
[10]Gaunitz F,Heise K,Schumann R,et al.Glucocorticoid induced expression of glutamine synthetase in hepatoma cells.Biochem Biophys Res Commun.2002;296(4):1026-32.
[11]Rowling MJ,Schalinske KL.Retinoic acid and glucocorticoid treatment induce hepatic glycine N-methyltransferase and lower plasma homocysteine concentrations in rats and rat hepatoma cells.J Nutr.2003;133(11):3392-8.
[12]Xu MJ,Hui N,Liu YJ.corticoids on activation of extracellular signal--regulated kinase 1 / 2 and cell proliferation in a human breast cancer cell line:MCF--7.Journal of Chinese Modern Gynaecology and Obstetrics.2005;2(2):100-103.
徐明娟,惠宁,刘宇健.ERK通路的激活状态对糖皮质激素抑制人乳腺癌细胞系MCF-7细胞增殖状态的影响.中华现代妇产科学杂志.2005:2(2):100-103.
[13]Wang H,Wang Y,Raybum ER,Hill DL,et al.Dexamethasone as a chemosensitizer for breast cancer chemotherapy:potentiation of the antitumor activity of adriamycin.modulation of cytokine expression,and pharmacokinetics.Int J Oncol.2007;30(4):947-53.
[14]Unterholzner S,Willhauck MJ,Cengic N,et al.Dexamethasone stimulation of retinoic Acid-induced sodium iodide symporter expression and cytotoxicity of 131-I in breast cancer cells.J Clin Endocrinol Metab.2006;91(1):69-78.
[15]Ouatas T,Halverson D,Steeg PS.Dexamethasone and medroxyprogesterone acetate elevate Nm23-H1 metastasis suppressor gene expression in metastatic human breast carcinoma cells:new uses for old compounds.Clin Cancer Res.2003;9(10 Pt 1):3763-72.
[16]Xu MJ,Fang GN,Cui Y,etal,Regulation of glucocorticoid receptor expression by dexamethasone in a human ovarian carcinoma cell line,Shanghai Medical Journal,2003;26(1):53-55.
徐明娟,方国恩,崔英,等.地塞米松对人卵巢癌细胞糖皮质激素受体的调节.上海医学.2003:26(1):53-55.
[17]Xia B,Chen YX,Chen GC,etal.Effect of glucocorticoid on cell cycle of human ovarian cancer cell line HO-8910.Academic Journal of Second Military Medical University.2003;24(5):499-501.
夏冰,陈玉霞,陈光椿,等.糖皮质激素对人卵巢癌细胞系HO-8910细胞周期的影响.第二军医大学学报.2003;24(5):499-501.
[18]Li ZB,Xia B,Lu J.The action of transforming growth factor β1 signal path in the inhibitory effects of glucocorticoid on proliferation of human ovarian cancer cell line HO-8910.Chinese Journal of Pathophysiology.2003;19(11):1542-1543.
李宗斌,夏冰,卢建.转化生长因子β1信号通路在糖皮质激素抑制人卵巢癌细胞HO-8910增殖中的作用.中国病理生理杂志.2003;19(11):1542-1543.
[19]Xu MJ,Cui Y,Fang GE,et al.Efects ofglucecorticoid on differentiation of 3AO:a human ovarian carcinoma cell line.Shanghai Medical Journal.2003;26(4):265-267.
徐明娟,崔英,方国恩,等.糖皮质激素对人卵巢癌细胞系(3AO)的诱导分化作用.上海医学.2003;26(4):265-267.
[20]Xu MJ,Hui N,Liu A,et al.Effects of glucocorticoids on cell cycle and CDKI p21/WAF1 in a human ovarian cancer cell line:3AO.Shanghai Medical Journal.2006;29(7):483-485.
徐明娟,惠宁,刘安,等.糖皮质激素对人卵巢癌细胞系3AO细胞周期分布及细胞周期蛋白激酶抑制因子p21/WAF1表达的影响.上海医学.2006:29(7):483-485.
[21]Xia B,Lu J,Wang G.Glucocorticoid modulation of extracellular signal-regulated protein kinase 1/2 and p38 in human ovarian cancer HO-8910 cells.Chin Med J(Engl).2003;116(5):753-6.
[22]Saunders DE,Christensen C,Wappler NL,et al.Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3,retinoic acid and dexamethasone.Anticancer Drugs.1993;4(2):201-8.
[23]Chen YX,Li ZB,Diao F,et al.Mechanism of inhibiting proliferation of human ovarian cancer cells of the line HO-8910 by dexamethasone:the role of RhoB signaling pathway.Zhonghua Yi Xue Za Zhi.2006;86(20):1400-4.
[24]Skjoeth J,Bjerre PK.Effect of glucocotricoids on ICP in Patients with a cerebral tumor.Acta Neurol Scand.1997;96(3):167-170.
[25]Anderson c,Jensen FT.Differances in blood - tumor - bawier leage of human intra cranial tumors:quantative monitoring of vaso genic edema and itd response to glucocorticoed treatment.Acta Neurochirwien.1998;140(9):919-924.
[26]Ding XM,Zhao NH.the research progress of glucocorticoid on adjunctive therapy in Patients with a cerebral tumor.Foreign Medical Sciences Section on Neurology &Neurosurgery.2001;28(3):156 -159.
丁新民,赵宁辉.糖皮质激素在颅内肿瘤辅助治疗中的研究进展.国外医学神经病学神经外科学分册.2001;28(3):156-159.
[27]Li JW,Zao J.The clinical analysis of therapeutic alliance 62 cancer patient'sanorexy.The Medicine Magazine Of China.2006;4(10):610-611.
李君旺 赵剑.联合治疗62例癌症患者厌食的临床分析.中国医学杂志.2006;4(10):610-611.
[28]Bao J,Hao JQ,Peng WR,et al.Study on Safety of Glucocorticoids to Malignant Tumors Complicated with Diabetes Mellitus.Journal of Cancer Prevention and Treatment.2005;12(13):1003-1006.
鲍健,郝吉庆,彭万仁:,等.癌症合并糖尿病患者应用糖皮质激素安全性的前瞻性随机对照研究,肿瘤防治杂志.2005;12(13):1003-1006.
[29]Li JB,Wu JB,Feng SY,et al.Low dose of corticosteroid in combination with methotrexate for the treatment of tumor-stage MF.Journal of Clinical Dermatology.2006;35(5):329-330.
李晶冰,吴建斌,冯素英,等.小剂量糖皮质激素联合甲氨蝶呤治愈肿瘤期蕈样肉芽肿2例,临床皮肤科杂志.2006;35(5):329-330.
[30]Ran RQ,Wu YX,Fu H.the regulation of glucocorticoids to the receptor of TNF in gastric cancer cells.Chinese Journal of Immunology.1997;(13):81-83.
冉瑞琼,吴裕炘,付华.糖皮质激素对人胃癌细胞肿瘤坏死因子受体的调节.中国免疫学杂志.1997:(13):81-83.
[31]Li ZB,Wang SW,Lu J.Up--regulation of transforming growth factor--β_1type Ⅱ receptor by glucocorticoid and its biological significance in cancer cells.International Journal of Emergency and Critical Care Medicine.2006;(3):1264-1266.
[32]Wang Y,Chen YX,Diao F,et al.Inhibitory Effects of Dexamethasone on Growth of Human Prostate Cancer Cell Line PC-3:The Possible Mechanism.Academic Journal of Second Military Medical University.2006;27(8):885-887.
王燕,陈玉霞,刁飞,等.糖皮质激素抑制人前列腺癌PC-3细胞系增殖的可能机制.第二军医大学学报.2006;27(8):885-887.
[33]Lu YS,Lien HC,Yeh PY,et al.Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors.World J Gastroenterol.2005;11(40):6373-80.
[34]Davies S,Dai D,Pickett G,et al.Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells.Gynecol Oncol.2006;101(1):62-70.
[35]Zhang LY,Gao BL,Sun FQ,et al.the reseach of the prognosis of certain digestive canal cancer with hydrocortisone.immune function and social psychic factor.Sichuan Mental Health.1996;9(2):79-81.
张理义,高柏良,孙芳卿,等.某些消化道癌的预后与糖皮质激素、免疫功能及社会心理因素的研究.四川精神卫生.1996;9(2):79-81.
[36]Xu MJ,Hui N,Liu YJ,et al.Regulation of glucocorticoid receptor expression by dexamethasone in a human breast cancer cell line MCF-7.Shanghai Medical Journal.2006;29(3):173-175.
徐明娟,惠宁,刘宇健,等.人乳腺癌细胞系MCF-7细胞中糖皮质激素受体的表达及其调节.上海医学.2006;29(3):173-175.
[37]Luo YL,Cao LS,Xue XY,et al.adrenal cortical tumor hypercortisolism(Report of 28 Cases).Journal of Fujian Medical College.1995;29(2):170-171.
罗义麟,曹林升,薛学义,等.肾上腺皮质肿瘤糖皮质激素症28例报告.福建医学院学报.1995:29(2):170-171.
[38]Jang XY,He HM,Xu FY,et al.the serum cortisol RIA of esophageal carcinoma perioperatively.Journal of Radioimmunology.1994;7(2):126-127.
姜秀云,何浩明,徐风英,等.食管癌手术前后血清糖皮质激素RIA.放射免疫学杂志.1994;7(2):126-127.
[39]Zhang C,Kolb A,Mattem J,et al.Dexamethasone desensitizes hepatocellular and colorectal tumours toward cytotoxic therapy.Cancer Lett.2006;242(1):104-11.
[40]Lui WY,Chi CW,Chang YF,et al.In vivo and in vitro growth stimulation of murine hepatoma cells by glucocorticoid.Anticancer Res.2002;22(3):1413-22.
[41]Iida N,Sugiyama A,Myoubudani H,et al.Suppression of arachidonic acid cascade-mediated apoptosis in aflatoxin B1-induced rat hepatoma cells by glucocorticoids.Carcinogenesis.1998;19(7):1191-202.
[42]Ioannesyants IA,Polevaya EB.Sensitivity of peripheral blood lymphocytes from breast cancer patients to glucocorticoids.Bull Exp Biol Med.2006;141(1):73-6.
[43]Pang D,Kocherginsky M,Krausz T,et al.Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis.Cancer Biol Ther.2006;5(8):933-40.
[44]Rodriguez F,Redondo M,Ruiz-Cabello F.Dexamethasone induces altered binding of regulatory factors to HLA class I enhancer sequence in MCF-7 breast tumour cell line.Cancer Immunol Immunother.1998;46(4):194-200.
[45]Sui M,Chen F,Chen Z,et al.Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.Int J Cancer.2006;119(3):712-7.
[46]Zhang C,Marme A,Wenger T,et al.Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas.Int J Oncol.2006;28(2):551-8.
[47]Runnebaum IB,Bruning A.Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.Clin Cancer Res.2005;11(17):6325-32.
[48]Millard RJ,McCredie S.Bladder cancer in patients on low-dose methotrexate and cortico- steroids.Lancet.1994;343(8907):1222-1223.
[49]Nesher,M;Shpolansky,U;Rosen,H,et al.The digitalis-like steroid hormones:New mechanisms of action and biological significance.Life Sciences.2007;80(23):2093-107.
[50]Gu w,Han KQ,Su YH,etal.Inhibition Action of Bufalin on Human Transplanted Hepatocellular Tumor and Its Effects on Expressions of Bcl-2 and Bax Proteins in Nude Mice.Journal of Chinese Integrative Medicine.2007;5(2):155-159.
顾伟,韩克起,苏永华,等.蟾毒灵对裸鼠人肝癌移植瘤的抑制作用及对Bc-122利Bax蛋白表达的影响.中西医结合学报.2007;5(2):155-159.
[51].Weidemann H,Salomon N,Avnit-Sagi T,etc.Diverse effects of stress and additional adrenocorticotropic hormone on digitalis-like compounds in normal and nude mice[J].J Neuroendocrinol.2004;16(5):458-63.
[52].Weidemann H.Na/K-ATPase,endogenous digitalis like compounds and cancer development -- a hypothesis[J].Front Biosci.2005;10:2165-76.
[53]Wu MC.The problem ahout the chinese medicines,effect,position and existing in prevention and cure hepatoma.Journal of Chinese Integrative Medicine.2003;1(3):163-164.
吴孟超.中医药在肝癌防治中的作用、地位和存在的问题.中西医结合学报.2003;1(3):163-164.